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Abstract 
Background:  
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease 
commonly affecting females of child-bearing age, hence hormonal changes in 
pregnancy are thought to play a role in disease activity – often necessitating 
changes in immunosuppression therapy. SLE is common in Cape Town, however, 
the effect of pregnancy on SLE and vice versa has not been well characterised. The 
aim of this study is to report on the pregnancy outcomes of patients with SLE 
presenting to the maternity department of Groote Schuur Hospital, Cape Town. 
 
Methods:  
This study was designed as a retrospective review of records of pregnant women 
known with SLE and followed up at the maternity section of Groote Schuur Hospital. 
The duration of the survey was from 1 January 2003 to 31 December 2013. Records 
were identified using the attendance registers in the relevant departments. 
 
Results:  
There were 61 pregnancies reviewed in 49 patients; 80.3% of the pregnancies were 
in patients of mixed ancestry and the rest (19.7%) in black African patients. The 
mean age at presentation of the current pregnancy was 27.2±5.0 years. Mean 
gestational age at presentation and delivery was 13.0 ± 6.0 weeks and 28.9 ± 9.8 
weeks respectively and 47.5% of the pregnancies were in patients with lupus 
nephritis (LN). Thirty-nine (63.9%) pregnancies reached the third trimester and 
11.5% of all pregnancies ended in the first trimester. There was a lower number of 
live births to mothers of African ancestry than to those of mixed ancestry (p=0.001). 
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In 55.7% of the pregnancies, no flare was reported while a renal flare was reported 
in 23%. Pregnancies in patients with LN had higher frequencies of flares (58.6% vs 
31.3%; p=0.032), pre-eclampsia (34.5% vs 12.5%; p=0.041), longer stay in hospital 
(12.0 ± 9.1 days vs 6.1 ± 5.1 days; p=0.004) and low birth weight babies (1.94 ± 1.02 
kg vs 2.55 ± 0.95 kg; p=0.046) than in patients without LN. Only 36 (59%) of the 
neonates were discharged home alive and of these 2 (5.6%) were to mothers of 
black African ancestry (p=0.001).  
 
Conclusion:  
Increased lupus activity in pregnant SLE patients may account for the increased 
deaths of neonates born to SLE mothers. Patients of black African descent and 
those with LN tend to have a poorer outcome. A multi-disciplinary approach to the 
management of SLE patients (of child-bearing age or pregnant) needs to be further 
evaluated. 
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Chapter 1: Literature Review 
1.1. Background: 
Recently Dr. Graca Machel, the widow of former president Nelson Mandela, argued 
that Africa may not be able to achieve some of its targeted Millennium Development 
Goals (MDGs) by the end of 2015.(1) Goal 4 of the MDGs aims to reduce child 
mortality by two thirds whereas Goal 5 aims to improve maternal health through the 
reduction of maternal deaths and to achieve universal access to reproductive health. 
These goals are one of the most important and measurable promises that the 
international community has pledged to women and children. In South Africa, almost 
one third of all childhood deaths are neonatal.(2) Immaturity accounts for almost 
45% of all early neonatal deaths, however, some progress has been made globally 
with reduction in early childhood mortality from 12.4 million in 1990 to 8.8 million in 
2008.(2,3)   
Obstetric haemorrhage and high blood pressure cause more than 50% of pregnancy 
and childbirth deaths globally. In South Africa, non-pregnancy related infections (for 
example, tuberculosis in HIV-positive women) alone account for 40%, obstetric 
haemorrhage 14% and hypertension 14% of all maternal deaths.(2) Although auto-
immune conditions were reported to account for 2.8% of overall maternal mortality in 
South Africa, the use of acute and chronic medications, especially 
immunosuppressive therapy in patients with auto-immune diseases and disease 
flares during pregnancy, can confound or even contribute to the major causes of 
mortality in these patients.(2) 
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Systemic lupus erythematosus (SLE) is an auto-immune disease of unknown 
aetiology and is characterised by multi-system involvement associated with variable 
clinical manifestations and disease course characterised by pathogenic auto-
antibody formation, immune complex deposition, and end organ damage.(4). This 
disease is a manifestation of complex interplay between genetic factors, hormones, 
auto-antibodies and environmental factors.(5) Like most auto-immune diseases it 
affects mostly women of child-bearing age (up to 90% at diagnosis) but all genders, 
ages and ethnic groups are susceptible.(6,7)   
Women with SLE not treated with alkylating chemotherapeutic agents like 
cyclophosphamide have normal fertility as autoimmune ovarian failure is rare and 
therefore, pregnancy is often uncomplicated in these patients. However, pregnancy 
in SLE patients is regarded as “high risk” as it may increase SLE activity with 
adverse short-term and long-term maternal outcomes: maternal death, stroke, 
hypertension, pre-eclampsia or eclampsia, nephritis with accelerated end organ 
damage requiring dialysis.(8) SLE also has adverse outcomes on pregnancy and 
foetal outcomes characterised by pregnancy loss, preterm birth, low birth weight, 
intrauterine growth retardation and neonatal death. In the United States of America 
(USA) it is estimated that there are 3 200 to 4 500 SLE pregnancies per year, and 
these are associated with a significantly increased rates of hypertensive disorders, 
higher risk of Caesarean delivery and longer hospital stays compared with the 
general obstetric population.(8, 9) Estimates of pregnancy and its effects on SLE and 
vice versa are not readily available in Africa. 
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1.2. Systemic Lupus Erythematosus 
1.2.1 Epidemiology of disease and clinical features: 
SLE is a chronic multi-organ, auto-immune, inflammatory disease which 
predominantly affects adults with propensity for women of child-bearing age of 
between 20 to 40 years, but may affect all age groups and both sexes with only 8% 
to 15% of SLE cases occurring in children.(10) Table 1 summarises the incidence in 
different countries both in the developed and developing countries.  
 
Table 1: Data of the estimated incidence of SLE in different countries  
 
COUNTRY 
 
Author (Year) [REF] 
 
       INCIDENCE 
 
USA# 
B 
Bernknopf et al (2011) (10) 
  
2 - 7 per 100 000 
persons   per annum 
United Kingdom Johnson et al (1995) (11) 3.8 per 100 000 persons 
per annum 
South Africa Jessop et al (1973) (12) 2.4 per 100 000 persons 
per annum 
India Kumar A (2002) (13) 3 per 100 000 persons 
per annum 
China (Hong Kong) Mok et al (2008) (14) 6.7 per 100 000 persons 
per annum 
# United States of America 
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The prevalence of SLE ranges from 14.6 to 68 cases per 100 000 persons in the 
USA; the paucity of data from Africa makes the true prevalence of SLE difficult to 
ascertain in Africa.(10) It has been suggested from published reports that women of 
African descent are up to four times more likely than Caucasian women to develop 
the disease. In South Africa, SLE has been reported to be more common in women 
of mixed ancestry than in Africans (12,15). However, whether the ongoing epidemic 
of HIV/Aids (common in black Africans) plays a modulating effect on this disease, 
presentation has not been critically assessed.  
Five- and 10-year survival for patients with SLE in the developed world has been 
reported to be about 88% - 96% and 75% - 95% respectively. (10) This has been 
attributed to the earlier diagnosis and more effective treatment options available in 
developed countries, which have effectively increased the 20-year survival rates to 
an estimated 80%.(10) Studies from South Africa show a 10-year survival rate of less 
than 40%; although this figure is compounded by a high rate of loss of follow-up of 
patients. (5) 
1.2.2 Classification criteria: 
Over the years there has been a concerted effort for development of a tool or criteria 
that is easy to apply and adapt for the diagnosis and classification of SLE. Siegel 
and Lee described early criteria in 1962 in an effort to standardise diagnosis and 
classification of SLE, and subsequently 14 criteria were selected in 1971 by the 
American College of Rheumatology (ACR) as a classification criteria, with only four 
criteria needed to make a diagnosis.(16) In 1982 the ACR criteria were published 
and included the ANA test and reduced to 11 criteria. In 1997 the ACR criteria were 
revised by the committee and included anti-phospholipid antibodies as one of the 
criteria as proposed by MC Hochberg and the item “LE preparation” was 
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deleted.(16,17) The attempt has always been to ensure a consistent definition of 
SLE for purposes of research and surveillance of the disease.   
The 1982 ACR criteria have been validated, but the subsequent revised criteria of 
1997 have not been validated. The Systemic Lupus International Collaborating 
Clinics (SLICC) group, an international group of investigators dedicated to SLE 
clinical research, had undertaken to revise the SLE classification criteria to address 
multiple concerns that have arisen since the development of the 1982 ACR criteria.  
A formal assessment of the important clinical manifestations of SLE and the 
limitations of the 1982 ACR criteria, conducted by the SLICC group, was published in 
2004, highlighting possible duplication of highly correlated terms relating to 
cutaneous lupus such as malar rash and photosensitivity. The need to use new 
standards in the quantification of proteinuria; limitation to seizures or psychosis 
without any other cause for neurological manifestation of SLE and omitting many 
other neurological manifestations of SLE; immunological manifestation omission of 
low complement levels and new information regarding anti-phospholipid antibodies 
and the inclusion of patients who did not satisfy any of the criteria for immunological 
disorder, being classified as having SLE.(17)   
In 2012 the SLICC criteria were published with 17 criteria. Refer to appendix 1(17).  
The proposed classification rule is as follows:  
“Classify a patient as having SLE if he or she satisfies four of the clinical and 
immunological criteria used in the SLICC classification criteria, including at least one 
clinical criterion and one immunological criterion, OR if he or she has a biopsy-
proven nephritis compatible with SLE in the presence of ANAs or anti-ds DNA 
antibodies.”    
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The SLICC classification criteria have been validated in studies involving multi-centre 
population sample versus the 1997 revision of the ACR criteria which were never 
validated, but it should be noted that the SLICC criteria, as is the case with the 
original revised ACR criteria, have not been tested for purposes of diagnosis.(17) 
Lupus nephritis is present if an SLE patient is shown to have proteinuria more than 
500mg/day or when the cellular casts in the urine and/or histologically proven.(17,18) 
Urine abnormalities raise the suspicion of nephritis but confirmation requires renal 
biopsy. Lupus nephritis is histologically categorised into six classes according to the 
International Society of Nephrology – Renal Pathology Society (ISN/RPS) 
classification as shown in Table 2. The presence of proliferative forms of LN has 
been demonstrated to be a predictor of poor outcome in SLE patients. 
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Table 2: International Society of Nephrology – Renal Pathology Society 
(ISN/RPS) Classification of Lupus Nephritis (19) 
 
LN class 
 
Histological description 
Class I Minimal mesangial lupus nephritis 
Class II Mesangial proliferative lupus nephritis 
Class III Focal lupus nephritis (<50% glomeruli) 
III (A) Active lesions 
III (A/C) Active and chronic lesions 
III (C)  Chronic lesions 
Class IV Diffuse lupus nephritis (>50% glomeruli) 
 Diffuse segmental (IV-S) or global (IV-G) 
IV (A) Active lesions 
IV (A/C) Active and chronic lesions 
IV (C) Chronic lesions 
Class V Membranous lupus nephritis 
Class VI Advanced sclerosing lupus nephritis 
 (≥90% globally sclerosed glomeruli without residual 
activity) 
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1.2.3 SLE disease activity assessment: 
Since SLE is a chronic disease, its characteristics are of continued disease activity 
and natural history of progressive accumulation of injury of the same organ at 
diagnosis, or further involvement of new organ systems over its chronic history even 
with appropriate management. Three patterns of disease activity have been 
recognised: 
• Remitting relapsing pattern (flare) 
• Chronically active disease with persistent disease symptoms and clinical or 
laboratory signs 
• Long quiescence or remission.   
The use of clinical evaluation, laboratory investigations and standardised disease 
activity tools (for example, SLEDAI (20), BILAG (21), ECLAM (22), SLAM (23) ) can 
be employed to differentiate between the different disease patterns of SLE. 
The SLICC/ACR Damage Index measures cumulative organ damage after the 
diagnosis of lupus and is updated yearly; and has been validated and proven reliable 
to determine cumulative damage of SLE over the determined time period or years in 
patients with the disease. Poor prognosis has been associated with higher damage 
scores early in the disease with associated high mortality. The SLICC/ACR Damage 
Index tool, together with the disease activity indices, complement each other to 
determine/predict or prognosticate outcomes of SLE patients. (24)  
1.2.4 SLE and pregnancy: 
 A female patient with SLE who becomes pregnant faces a potential risk to her 
health and that of her foetus. SLE can have a severe disease flare which may be 
potentially life-threatening and other drugs used to control the disease may be 
teratogenic and foetotoxic. Pregnancy seems to be a risk factor for SLE flare with 
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estimated two- to three-fold increase in SLE activity during pregnancy and 
puerperium. The estimation is 35- to 70% of all SLE pregnancies will have a flare but 
with a lower risk of moderate to severe flare, being 15- to 30%.(8) Most flares are 
mild, cutaneous and joint disease being the most common manifestations.  
Pregnancies in patients with SLE and underlying chronic hypertension, renal 
disease, anti-phospholipid antibodies, and anti-SSA (Ro) and anti-SSB (La) 
antibodies are high risk for adverse outcomes.(25-29)(30) In general, women with 
SLE uncomplicated by hypertension or renal impairment prior to conception, usually 
have successful pregnancies, and pregnancy does not have an adverse effect on the 
progression of renal disease.(31) SLE in remission for at least six months prior to 
conception minimises the risk of flares during pregnancy and the discontinuation of 
hydroxychloroquine before or during pregnancy is associated with significant higher 
risk of SLE flares.(32) It is likely that therapy changes may also have major influence 
on pregnancy risk, therefore  fetotoxic drugs, eg Mycophenolate mofetil, angiotensin 
converting enzyme inhibitors/ angiotensin receptor blocker, cyclophosphamide and 
methotrexate should be avoided.  
The understanding of SLE and advancement in management has seen the disease 
no longer a contraindication for pregnancy with the exception of organ-system 
complications like pulmonary hypertension and advanced chronic kidney disease 
being a relative contraindication to falling pregnant. According to Clark et al (33), in 
the past 40 years there has been a decrease in the rate of pregnancy loss rates in 
patients with SLE and this has been attributable to disease management and 
recognition that inactive disease in contrast to stable disease is an important 
consideration in reducing both maternal and foetal morbidity. The rate of loss in SLE 
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pregnancies over the past 40 years decreased from a mean of 43% between 1960 
and 1965 – to 17% between 2000 and 2003.(33) 
Also, SLE carries a two- to three-fold risk of foetal loss compared to the general 
population and the risk is increased in mothers with high disease activity, anti-
phospholipid antibodies and active lupus nephritis.(25) SLE pregnancies have poor 
outcomes compared with non-SLE pregnancies even after adjusting for modifiable 
risk factors like obesity, tobacco smoking, and alcohol or drug abuse during 
pregnancy. Diabetes mellitus and hypertension is a common co-morbid diagnosis 
attributable to disease and treatment complications which places SLE pregnancies at 
higher risk than other women. Pregnancy complications like Caesarean section, pre-
term labour, intrauterine growth restriction, pre-eclampsia and eclampsia are two- to 
four-fold higher in women with SLE than the non-SLE population as summarised in 
Table 3 below.(25) 
Table3: Pregnancy complications in SLE pregnancies (25) 
Pregnancy complications Percentage of SLE deliveries 
with the complication 
Percentage of non- SLE deliveries 
with the complication 
 
Caesarean section 
 
36.6% 
 
25.0% 
Pre-term labour 20.8% 8.1% 
Intrauterine growth restriction 5.6% 1.5% 
Pre-eclampsia 22.5% 7.6% 
Eclampsia 0.5% 0.09% 
 
 
SLE pregnancies have high maternal mortality rate ranging from 325-1100/100 000 
live births in the USA, a rate that is more than 20 times higher than the mortality rate 
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for the non-SLE population.(25) Clowse et al have shown in their study that 
compared to the general population, SLE pregnancies had higher risk of medical 
complications like thrombotic complications (10-fold higher), infectious complications 
caused both by disease-related immune dysregulation and immunosuppressive 
therapy (five- to eight-fold higher) and haematological complications as summarised 
in Table 4 below. 
Table 4: Medical complications in SLE pregnancies (25) 
Medical complications Percentage of SLE deliveries 
with the complication 
Percentage of non-SLE 
deliveries with the 
complications 
 
Thrombotic Complications 
  
Stroke 0.32% 0.03% 
Pulmonary embolus 0.4% 0.04% 
DVT* 1.0% 0.01% 
   
Infectious complications   
Sepsis 0.5% 0.1% 
Pneumonia 1.7% 0.2% 
   
Haematological complications   
Transfusion 2.7% 0.5% 
Postpartum haemorrhage 4.5% 3.3% 
Antepartum bleeding 2.0% 0.4% 
Anemia at delivery 12.6% 6.8% 
Thrombocytopenia 4.3% 0.4% 
   
*Deep vein thrombosis   
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1.2.5 Physiological changes in pregnancy that can mimic SLE: 
Certain physiological changes that occur in pregnancy can sometimes mimic 
symptoms of SLE. These changes sometimes can make the diagnosis or flare of 
SLE difficult.  Increased blood volume in pregnancy (up to 50% increase) can cause 
anaemia and also be responsible for thrombocytopenia in 5- to 10% of pregnant 
women.(8)   
Also, changes in the urinary system such as the increased renal blood flow and 
dilatation of the collecting system can cause proteinuria and haematuria through an 
increase in glomerular filtration rate that occurs in early pregnancy and bleeding from 
small venules in dilated collecting system, respectively.  
Musculoskeletal changes such as muscle and joint pain commonly seen in 
pregnancy may be a mimic of some of the musculoskeletal features of SLE.  
During pregnancy, complement C3 and C4 may rise by 10- to 50% secondary to 
increased liver protein synthesis, and thus a flare with complement activation may 
occur despite apparently normal levels of C3 and C4.(34) Conversely, C3 and C4 
may be low in the absence of SLE flare, probably due to synthetic defects. However, 
the drop of C3 or C4 levels by more than 25%; is reasonable to be attributed to 
disease activity.(35) 
1.2.6 Pregnancy, cytokines and disease activity in SLE 
1.2.6.1 Hormones and cytokines in normal pregnancy: 
Pregnancy introduces a unique situation where genetically different individuals co-
exist in a single body for up to an average of between 38 and 40 weeks, which has 
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initiated a lot of research to understand the mechanism of tolerance. Hormones are 
produced by the corpus luteum and trophoblast with complex alterations the 
hypothalamus-pituitary-adrenal axis with profound influence in functioning of the 
innate and adaptive immunity from proliferation, distribution and functioning of 
immune cells.(36) The interaction of myeloid dendritic cells which are antigen 
presenting cells results in activation of T cells under the influence of cytokines 
facilitated by chemokines. Cytokines and chemokines regulate T-helper cells 
function, which are effector cells in immune response. T-helper cells are involved in 
interactions with antigen presenting cells and with the B cells which form the 
antibodies, via specific signalling pathways and cytokine production. Interplay 
between hormones, cytokines and effector T-helper cells is important for a 
successful pregnancy.(36) The CD4+ T-helper cells have type 1 cells (TH1) which 
are involved in the cell mediated immunity, while the type 2 (TH2) cells are involved 
with humoral (antibody) mediated immunity.  Tom Wegmann in 1993 proposed that 
successful pregnancy was a TH2 process with suppression of TH1 cell 
response.(37)  TH1 cells produce different cytokines (interferon gamma (IFN γ), 
tumor necrosis factor α (TNF α), interleukin-12 (IL-12) and interleukin 2(IL-2)) and 
TH2 produce interleukin 4 (IL-4), interleukin 10 (IL-10) and interleukin 13 (IL-13). 
Uncomplicated successful pregnancies are associated with suppression of TH1 
response and TH 1 type response in reproductive failures.(38)(36) TNF-α and IFN-γ 
are necessary in early pregnancy for successful implantation and development of 
placenta and may be detrimental in late pregnancy. (36, 39, 40) The placenta 
increases the production of IL-10 during late pregnancy which down regulates the 
production of pro-inflammatory cytokines by TH1 cells and macrophages, hence 
cytokine expression at the feto-maternal interface is regulated according to the stage 
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of pregnancy to create optimal conditions for foetal development.(41) There are 
other subset of CD4+ T-helper cells which are T-helper 17 cells (TH 17) which are 
pro-inflammatory and are defined by production of interleukin-17 (IL-17); and 
regulatory T-helper cells (TREG) which are key cells type to self-regulate against 
attacks and destruction of own. TREG suppress CD4+ and CD8+ T-cell proliferation 
and also antigen presenting cells through production of interleukin-2 (IL-2). There is 
a close relation for differentiation of T cells either to TREG or TH 17 cells, which is 
dependent on the presence of transformation growth factor β1(TGFβ1). Presence of 
TGFβ1 favours TREG while in the co-presence of IL-6 predominant differentiation 
into the TH17 subtype occurs.(42) Properly functioning TREG are important for 
successful healthy pregnancy, they are critical for maternal immune tolerance both 
locally in the uterus, and in the systemic circulation.(43) (44,45) According to Tower 
et al, the generation of TREG seems to be controlled by FOXP3 enhancer element 
and they recognise the paternal antigens and have inhibitory effect on maternal 
immune effector cells.(43) TREG cells increase in the first trimester, peak in the 
second trimester and dip post-partum. 
In uncomplicated non-SLE pregnancy there is increase in regulatory molecules that 
have modulator effect on circulating cytokines and cytokine actions. These are 
soluble interleukin receptors which block binding and uptake of certain cytokines in 
cells. Among them are TNF receptors (TNFR), interleukin 1 receptors (IL-1Ra) which 
buffer the biological effect of both the TNF-α and IL-1β, and interleukin 6 receptors 
(IL-6R). (41) The IL-Rs have been shown to increase in pregnancy especially in the 
second and third trimester in women with healthy pregnancies. In healthy 
pregnancies the secretion of cytokines by peripheral lymphocytes and monocytes 
changes with diminished pro-inflammatory response over the course of pregnancy. 
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(36,46) There is decrease in TNF-α, IL-1β and IL-6 with progression of pregnancy, 
while IL-4 and IL-10 remain stable.(47) Progesterone induces the expression of the 
immune-modulatory protein, progesterone-induced blocking factor (PIBF) by the 
peripheral lymphocytes. PIBF is associated with an increase of IL-10 production 
which has an anti-inflammatory effect. (36,48,49) Oestrogen has multiple effects on 
the immune system, it can up-regulate multiple genes like bcl-2 gene on B cells, 
blocking tolerance induction on naïve B cells and enhance transitional B cells’ 
resistance to apoptosis expanding the population of marginal zone B cells. Thus 
oestrogen may facilitate the differentiation and maturation of pathogenic naïve auto 
reactive B cells.(50,51) Oestrogen can influence T cells by increasing the expression 
of calcineurin, a calcium/calmodulin-activated protein phosphate enzyme playing a 
key role in regulating the transcription factor (nuclear factor of activated T cell – NF-
AT) during T cell activation which in turn upregulate the expression of IL-2 which 
stimulates the growth and differentiation of T cell response and production of other 
cytokines.(52, 53) Oestrogen has also been shown in vitro to reduce apoptosis of 
peripheral mononuclear cells and to reduce TNF-α; and it can activate dendritic cells 
while prolactin has inhibition effect. (54) In viewing all the data and evidence, 
pregnancy is a well-balanced immunological environment that doesn’t favour one 
immunological state over the other, but a milieu that changes with each stage of 
pregnancy to favour successful pregnancy outcomes. 
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1.2.6.2 Hormones and cytokines in pregnant SLE patient: 
In diseases like SLE and other connective tissue diseases there is both T cell 
signalling and cytokine level derangement, thus generation of high-affinity auto-
antibodies and cell mediated tissue damage.(55) The immune system’s capacity to 
self-regulate via T cells is also compromised in SLE.(43, 56) Pro-inflammatory TH 17 
cells are usually found in high numbers in inflammatory sites in SLE and conditions 
like pre-eclampsia and recurrent pregnancy loss.(43) IL-17 is a cytokine capable of 
stimulating the inflammatory response through chemokines and cytokine production, 
and proliferation and recruitment of neutrophils, macrophages and lymphocytes.(42) 
As mentioned above, TREG cells increase in the first trimester, peak in the second 
trimester and dip post-partum. The TREG are lower in women with SLE compared to 
healthy women and this persists through the whole pregnancy; with a lower capacity 
to activate TGFβ1 in women with SLE.(43) This could suggest impaired pregnancy 
tolerance in SLE patients, which may explain increased pregnancy risks in this 
cohort of patients. 
Prolactin has dual effect, pro-inflammatory as oestrogen and also inhibitory to the 
immune system. High levels of prolactin can break tolerance of high-affinity DNA-
reactive B cells and T cell dependent autoreactive follicular B cells.(57) In small 
human and animal studies bromocriptine an anti-prolactin has been shown to reduce 
clinical activity of SLE par to hydroxychloroquine, which may be proof that increase 
prolactin may be a driver of disease flare in pregnancy and pueperium.(54,57-59) 
 These immunological changes in pregnancy may be useful in explaining some of 
the adverse events that occur in SLE patients. 
  
26	  
	  
1.2.7 Medical conditions in pregnancy that make diagnosis SLE flare difficult: 
Thrombocytopenia, while potentially a marker of SLE activity can occur in pregnancy 
as a physiological phenomenon but levels less than 70 x 10 9 /L are in keeping with a 
pathological process. Common pathological causes of thrombocytopenia during 
pregnancy are: 
•Pre-eclampsia, eclampsia HELLP syndrome (haemolysis, elevated liver enzymes 
and low platelet count) associated peripheral consumption in microangiopathic 
haemolytic anaemia (MAHA)   
•Foetal demise  
•Antiphospholipid syndrome (APS) 
•Heparin therapy, heparin-induced thrombocytopenia (HIT) caused by formation of 
abnormal antibodies that activate platelets that can predispose to thrombosis. 
Thrombocytopenia, anaemia are also a features of normal pregnancy, pre-
eclampsia, eclampsia with HELLP syndrome and active SLE.  Lymphopenia 
(1,000/mm 3 at least once) and direct Coombs’ test in the absence of haemolytic 
anemia are features in keeping with active SLE. 
The discontinuation of angiotensin converting enzyme inhibitors (ACE-I) in 
pregnancy can precipitate increase in proteinuria, but the increase of greater than 
double of baseline would indicate either worsening lupus nephritis or pre-eclampsia.  
Proteinuria, haematuria and rising creatinine is also of feature of pre-eclampsia and 
severe eclampsia, which might be difficult to distinguish from active lupus nephritis.  
An active urinary sediment with rising or positive anti ds-DNA antibodies with low C3 
and C4, proteinuria with UPCR greater than 2g/ml or 2g/24 hour urine  is more in 
keeping with active lupus nephritis. It should also be noted that the development of 
proteinuria or the rise of in chronic kidney disease of whatevere cause may be a 
feature of kidney damage. Hyperuricaemia and abnormal liver function tests are 
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unusual in lupus flare and more indicators of pre-eclampsia.  (60)  Table 5 below has 
summarised the different clinical scenarios or conditions which might make diagnosis 
of SLE difficult during pregnancy. 
Table 5: Differential diagnosis between physiological pregnancy, lupus flare, 
pre-eclampsia and HELLP syndrome (60) 
Signs and  
symptoms 
Physiological 
pregnancy 
Active SLE Pre-
eclampsia 
HELLP syndrome 
Anaemia Haemolytic 
anaemia 
unusual 
Haemolytic 
anaemia 
with positive 
direct 
Coomb’s 
and 
associated 
leucopenia 
Usually 
absent 
MAHA: high LDH> 
600UI/ml 
Schistocytes at 
peripheral blood smear 
Thrombocyopenia >70 x 109/L Normal or 
low 
Normal or 
low in 
severe pre-
eclampsia 
<70 x 109/L 
Serum creatinine low Normal or 
high 
Normal or 
high 
Normal 
Proteinuria ≤ 300mg/24h Normal or ≥ 
2g/24h 
Normal 
≥300mg but 
usually ≤ 
2g/24h 
Normal or rising 
Blood pressure Low to normal Normal or 
rising 
>140/90 >140/90 
Liver functions 
tests 
Normal  Normal or 
high 
Normal High ALT & AST > 
1000UI/ml 
Complement C3 & 
C4 
Rising Normal or 
low 
Normal  High levels of split C3a 
& C5a 
Anti-ds DNA 
antibodies 
Negative  Positive or 
rising 
Negative Negative 
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1.2.8 Lupus nephritis and pregnancy outcomes: 
A number of issues arise in the pregnant patient with lupus nephritis (LN): 
1. Pregnancy may increase lupus flares with adverse short and long term effects on 
renal function and potentially leading to accelerated end-stage renal disease 
2. Active LN and advanced chronic kidney disease (CKD) are relative 
contraindication to conceive because of increased risk for maternal and foetal 
complications, including spontaneous miscarriage and premature delivery, IUGR, 
and pre-eclampsia. 
Almost 40 to 60% of SLE pregnancies will experience some flare during the course 
of pregnancy, but renal involvement is not more common in pregnancy as compared 
to non-pregnant patients with SLE although lupus nephritis may manifest for the first 
time in pregnancy.(42) Although pregnancy itself in patients with LN or the 
occurrence of LN flare during pregnancy may not have a long term deleterious on 
renal function, baseline creatinine or stage of CKD, it can however influence the 
prognosis of the renal disease in these pregnancies. The presence of anti-
phospholipid antibodies during pregnancy has been associated with increase in 
diagnosis of LN and nephritis flares with increased premature births. 
Some studies have reported poor clinical outcomes in patients with LN (both active 
and inactive disease) with pregnancy; losses up to 60% have been reported in 
patients with active LN while lower rates of pregnancy loss of 8- to 36% in cohorts 
have been shown in LN patients with inactive disease.(30) The high percentages 
and variations are largely attributed to study designs which are mostly retrospective 
and having small number of patients; different definitions, statistical methods, bias 
and outcomes.  Recent studies though have shown better outcomes of 13 to 27 % 
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pregnancy loss (excluding induced termination of pregnancy) in pregnancies of LN 
patients that might be a reflection of better understanding of LN and changing clinical 
environment with emergence of new therapies.(29,30,61)  
In a systemic review and meta-analysis of pregnancy outcomes in patients SLE and 
LN, Smyth et al (2010) found that lupus flare which was 25.6% and accounted for 
almost a quarter of all maternal complications. Lupus flare was one of the severe 
complications associated with maternal death occurring in 1 % of all maternal 
complications others included opportunistic infections, sepsis and renal impairment 
from other causes. Meta regression analysis showed statically significant association 
between active LN and maternal complications of hypertension and foetal 
complications of premature birth; history of nephritis and maternal hypertension and 
pre-eclampsia. The same study showed that there was no statically significance in 
LN histological subtypes between foetal and maternal complications. (30) 
The available evidence shows that renal flare is more likely to occur in women with 
active disease at conception and active LN seems to increase both maternal and 
foetal pregnancy adverse outcomes especially when associated with APA in 
pregnant SLE patients. There is limited evidence of different LN histological subtypes 
associated with adverse foetal and maternal outcomes. Restriction on use of 
fetotoxic medications also infuences the pregnancy outcomes in LN. 
1.2.9 Pregnancies in SLE patients versus pregnancies in the general 
population: 
According to Clark et.al in the past 40 years there has been a decrease in pregnancy 
loss rates in patients with SLE attributable to disease management and recognition 
that inactive disease in contrast to stable disease is an important consideration in 
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reducing both maternal and foetal morbidity.(33) Recent published data in the 
developed countries show favourable pregnancy outcomes with live birth rates in 85- 
to 90% of pregnancies.(30) Smyth et.al in their meta-analysis of 37 papers which 
included 2 751 pregnancies showed that almost one quarter of pregnancies were 
unsuccessful, and almost 39.4% of all live births were premature.(30) The poor 
predictor was mostly active lupus nephritis which was associated with premature 
births and gestational hypertension. This finding is in congruence with the only study 
in South Africa of SLE and pregnancy outcomes showed 77% success rate of 
pregnancy in patients with SLE and 39% of these births as premature.(62) The 
differences between these studies may be a reflection of access to better clinical 
resources including new therapeutic options, or this discrepancy in pregnancy 
outcomes may be a reflection of heterogeneity of study designs, populations 
included in the studies and perhaps the different prevalence of complications like 
lupus nephritis. The risk of early pregnancy loss or miscarriage (less than 20 weeks 
gestation) in SLE population is not markedly higher than the general population. It is 
estimated that 20% of pregnancies will end in miscarriage compared to almost 15% 
of clinically known pregnancies for the general population.(8)(63) 
1.2.10 Anti-phospholipid antibody syndrome (APS) in pregnancy: 
APS is a form of acquired thrombophilia mediated by auto-antibodies with resultant 
recurrent vascular (venous or arterial) thrombosis and/or recurrent pregnancy losses 
in the presence of auto-antibodies against phospholipid binding plasma proteins, 
mainly apolipoproteins β2 glycoprotein 1 (anti β2GP1) and prothrombin, and the 
other group of antibodies called lupus anticoagulant (LAC) and anti-cardiolipin 
antibodies(aCL)(64) The manifestation of APS can be primary or secondary if it 
occurs with other auto-immune diseases like SLE, scleroderma, Sjőgren’s syndrome, 
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dermatomyositis and rheumatoid arthritis. These auto-antibodies have prevalence of 
1- to 5% in the general populations especially common with progressive age and can 
be up to 37% in patients with SLE.(64)(65)    
The pathogenic mechanism of presence of antiphospholipid antibodies and adverse 
pregnancy outcomes is still not fully understood. The presence of placental 
thrombosis and infarction has been reported but thrombotic events don’t fully explain 
antiphospholipid antibodies mediated foetal loss. 
The presence APA has been shown to have positive association with poor outcomes 
in pregnancy including induced and spontaneous miscarriages, hypertension in 
pregnancy (pre-eclampsia and eclampsia) and premature birth.(66) The recurrence 
of miscarriage without underlying medical condition is not uncommon in the general 
population, being recorded in 1/100 or 1/200 women, but foetal deaths, after the 10th 
week of gestation, are infrequent in the general population.(67) A history of habitual 
spontaneous miscarriages (recurrent three or more pregnancy losses before 20 
weeks) is rare in the absence of conditions like genetic, hormonal or uterine 
abnormalities, but more common with anti-phospholipid antibody syndrome.(67,68)  
Factors like the previous miscarriage, or foetal death are the strongest predictor of 
further complications in women with APS. Anti-cardiolipin antibodies and LAC are 
important causes of foetal death and they increase the risk of foetal loss in 
pregnancy with a hierarchy of effect. Their presence even in the absence of renal 
disease is one of the predictors for development of pre-eclampsia.(69,70) The anti-
cardiolipin antibodies may be present in up of 50% of SLE patients as shown in the 
Greek study.(30,71) Presence of aCL antibodies in high titres has a direct predictive 
outcome of pregnancy with IgG-aCL associated with both early miscarriage and late 
foetal loss. The presence of LAC is also associated low birth rates with overall live 
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births of 73% and a prematurity rate of 37% even with different treatment modalities 
employed to improve outcomes.(72) LAC is strongly associated with recurrent foetal 
loss before 24 weeks as highlighted by in study by Guillermo Ruiz-Irastorza et al, 
with an odds ratio of 7.79.(25) Anti-β2GP1 are more predictive of early and severe 
pre-eclampsia and eclampsia as highlighted in several studies, with general anti-
phospholipid antibody syndrome carrying 20- to 50% risk of early and severe pre-
eclampsia and eclampsia.(68) The presence of APS in the best setting of First World 
management has the pregnancy success rate of 75- to 80% and high risk of 
complications like hypertension/pre-eclampsia, prematurity, or thrombosis that can 
take place during pregnancy and the puerperium.(29) 
1.3 Summary: 
Systemic lupus erythematosus is a complex disease of unknown aetiology and with 
variable mode of presentation. It is an illness that predominantly affects females of 
child-bearing age. Changes in the hormone profiles of females with SLE during 
pregnancy may contribute to a flare (worsening activity) of disease and could 
potentially be associated with maternal and foetal morbidity and mortality. The 
presence of kidney disease in lupus has generally been shown to be a poor 
prognostic factor and could therefore be an important predictor of pregnancy 
outcome for the mother and her foetus. The ACR guidelines have therefore 
recommended that women of child-bearing potential with active or prior LN receive 
counselling regarding pregnancy risks conferred by the disease and its 
treatments.(18) 
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The outcomes of SLE mothers and their foetuses are not known at Groote Schuur 
Hospital – and whether the presence of kidney disease or other demographic factors 
in SLE affects pregnancy outcomes in this group of patients is not known.  
A retrospective study of pregnant SLE patients presenting and treated at the 
maternity department of Groote Schuur Hospital will be carried out. This study will 
therefore broadly enable us to identify factors that are associated with poor maternal 
and foetal outcome and specifically factors that can be modified by us in order to 
reduce maternal and foetal morbidity and mortality of our patients with SLE (with or 
without nephritis).   
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Abstract 
Background:  
Systemic lupus erythematosus (SLE) is a multi-system auto-immune disease 
commonly affecting females of child-bearing age, hence hormonal changes in 
pregnancy are thought to play a role in disease activity – often necessitating 
changes in immunosuppression therapy. SLE is common in Cape Town, however, 
the effect of pregnancy on SLE and vice versa have not been well characterised. 
The aim of this study is to report on the pregnancy outcomes of patients with SLE 
presenting to the maternity department of Groote Schuur Hospital, Cape Town. 
 
Methods:  
This study was designed as a retrospective review of records of pregnant women 
known with SLE and followed-up at the maternity section of Groote Schuur Hospital. 
The duration of survey was from the 1st January 2003 to 31st December 2013. 
Records were identified using the attendance registers in the relevant departments. 
 
Results:  
There were 61 pregnancies reviewed in 49 patients; 80.3% of the pregnancies were 
in patients of mixed ancestry and the rest (19.7%) in black African patients. The 
mean age at presentation of the current pregnancy was 27.2±5.0 years. Mean 
gestational age at presentation and delivery was 13.0 ± 6.0 weeks and 28.9 ± 9.8 
weeks respectively and 47.5% of the pregnancies were in patients with lupus 
nephritis (LN). Thirty nine (63.9%) pregnancies reached the third trimester and 
11.5% of all pregnancies ended in the first trimester. There was a lower number of 
live births to mothers of African ancestry than to those of mixed ancestry (p=0.001). 
In 55.7% of the pregnancies, no flare was reported while a renal flare was reported 
in 23%. Pregnancies in patients with LN had higher frequencies of flares (58.6% vs 
31.3%; p=0.032), pre-eclampsia (34.5% vs 12.5%; p=0.041), longer stay in hospital 
(12.0 ± 9.1 days vs 6.1 ± 5.1 days; p=0.004) and low birth weight babies (1.94 ± 1.02 
kg vs 2.55±0.95 kg; p=0.046) than in patients without LN. Only 36 (59%) of the 
neonates were discharged home alive and of these 2 (5.6%) were to mothers of 
black African ancestry (p=0.001). The frequency of neonates discharged home alive 
was not different between for mothers with lupus nephritis and those without lupus 
nephritis (p=0.270).    
 
Conclusion:  
Increased lupus activity in pregnant SLE patients may account for the increased 
deaths of neonates born to SLE mothers. Patients of black African descent and 
those with LN tend to have a poorer outcome. A multi-disciplinary approach to the 
management of SLE patients (of child-bearing age or pregnant) needs to be further 
assessed for better outcomes 
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Introduction: 
Systemic lupus erythematosus (SLE) is an autoimmune disease of unknown 
aetiology and is characterized by multi-system involvement associated with variable 
clinical manifestations and disease course that is characterised by pathogenic 
autoantibody formation, immune complex deposition, and end organ damage.1 SLE 
is a manifestation of complex interplay between genetic factors, hormones, 
autoantibodies and environmental factors.1 Like most autoimmune diseases it affects 
mostly women of childbearing age; up to 90% at diagnosis; all genders, ages and 
ethnic groups are susceptible. 2, 3 
The evolution of SLE is known to be changed by natural hormonal events that could 
occur in a woman’s life (e.g. menstrual period, menopause and pregnancy). The 
care of pregnant women with SLE as well as pregnancy outcomes in women with 
SLE has been reported to have significantly improved even though these reports are 
often from developed countries.4 Pregnancy in SLE is, however still considered 
“high-risk” especially in developing countries where all the facilities or options of 
therapy may not be available. Adverse short term and long term maternal outcomes 
that have been reported in SLE includes maternal death, stroke, hypertension, pre-
eclampsia or eclampsia and LN with accelerated end organ damage requiring 
dialysis.5 In one study, SLE patients were twice more likely to have a caesarean 
section and their neonates were more likely to be of low birth weight, preterm 
delivery and had higher frequencies of congenital malformations than reference 
patients.6 
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Data is limited from countries in Africa, although one study from South Africa 
reported no loss to maternal life, 13% occurrence of mild flares, 33.3% pre-
eclampsia, 77% live births and 14% intra-uterine growth retardation; the study, 
however, did not look for factors associated with the pregnancy outcomes.7  
We therefore sought to retrospectively assess the impact of pregnancy on SLE and 
vice versa at Groote Schuur Hospital, Cape Town and to identify, where possible, 
factors associated with the outcome. 
Methods: 
This study was approved by the University of Cape Town Human Research Ethics 
Committee (HREC REF 038/2013). Records of patients known with SLE meeting the 
American College of Rheumatology criteria for SLE 1982 (revised in 1997) who 
presented to the GSH gynaecology emergency unit, ante-natal clinic or maternity 
wards in gestation from 1 January 2003 to 31 December 2013 were accessed for 
retrospective analysis. The patients’ records were identified using the attendance 
registers in the relevant departments (Rheumatology and Nephrology) involved in 
the care of patients with SLE. Patients were excluded if they didn’t meet the 
American College of Rheumatology criteria for SLE, if they had mixed connective 
tissue disease of those who presented to the Obstetrics department outside the 
period of the study. Records obtained included ethnicity, age of the patient at 
presentation, gestational age at presentation, history of chronic diseases 
(hypertension, diabetes) and current and past gynaecological and obstetric history.  
Complications that occurred during pregnancy such as pre-eclampsia, flare of SLE 
(defined as a change in clinical and/or serological parameters requiring adjustment 
of doses of immunosuppression were categorised as renal, skin, joint, or any 
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combination of these)8, pre-term delivery, and method of delivery were documented. 
Pre-eclampsia was as diagnosed by the attending obstetrician. Duration of maternal 
hospitalisation and gestational age at delivery were also recorded. Foetal outcomes 
were documented as birth weight (normal or low birth weight), duration of 
hospitalisation after delivery and status of the neonate at discharge (alive or died).  
Patients were treated in line with the rheumatology and nephrology divisions 
protocols for the management of SLE.  
 
Definition of terms: 9 
Birth weight and gestational age:  
Low birth weight: neonatal weight 1000 – 2499g 
Pre-term baby: birth at gestational age of 28 – 37 weeks 
Term baby: birth at gestational age of > 37 weeks 
Pregnancy outcomes: 
Miscarriage: pregnancy loss from time of conception until 24 weeks and 28 weeks of 
gestation or delivery of foetus below 500g in weight or  
Pre-term labour: the onset of labour before 37 completed gestational weeks. 
Term labour: the onset of labour after 37 completed gestational weeks. 
Foetal outcomes 
A stillbirth: is a baby born dead. The legal definition used in South Africa is baby born 
after 28 weeks of gestation or weight of 1000g or more. 
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Neonate: an alive new born baby 
Statistical Analysis: 
The data were analysed using IBM SPSS Statistics 21 software (SPSS, Chicago, IL). 
Categorical variables were presented as percentages and continuous variables as 
means ± SD. Comparison was made between pregnancies in patients with LN and 
those without LN using the Student’s t-test, chi-square test or Fisher’s exact test. 
Significant P-value was taken as P<0.05. 
Results: 
1. Baseline demographics features of patients 
Initially, we reviewed the data of 62 pregnancies in 50 women. One patient was 
excluded as there was inadequate evidence to show that she fulfilled the ACR 
criteria for the diagnosis of SLE. Hence, the baseline features of 61 singleton 
pregnancies (49 women) that fulfilled the ACR classification criteria for a diagnosis of 
SLE are shown in Table 1, and 12 women had more than one pregnancy during the 
course of the study. Of the 49 women 12 had an index diagnosis of SLE.  The mean 
age at presentation (for the assessed pregnancy) was 27.2 ± 5.0 years, most of the 
patients (80.3%) were of mixed ancestry and 47.5% of the pregnancies occurred in 
patients known with biopsy proven LN (Figure 1).  
Treatment records at presentation included use of glucocorticoids (67.2%), 
cyclosporine A (9.8%), Azathioprine (23.0%), chloroquine (50.8%) and various anti-
hypertensive agents (none – 50.8%, 1 anti-hypertensive agent – 23.0%, 2 or more 
anti-hypertensive agents – 26.2%) (not shown in Table). 
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2. Maternal and foetal features and outcomes 
Table 2 and 3 summarises the recorded maternal and foetal features and outcomes 
from pregnancy to time of delivery. The mean gestational age at delivery was 28.9 ± 
9.8 weeks, most of the deliveries (63.9%) occurred in the third trimester of 
pregnancy and over half of deliveries (52.5%) were either by evacuation of retained 
products of conception or Caesarean section. Pre-eclampsia occurred in 23% of all 
the pregnancies. A lupus flare was documented in 44.3% of pregnancies; most flares 
predominantly affected the kidneys (23.0%) (Figure 2).  
At birth, 64% of neonates were born alive, 9.8% were stillbirths (Table 3). However, 
only 59% of the neonates were discharged home alive as three infants died shortly 
after birth. The average birth weight of infants was 2.24 ± 1.02 kg and 54.5% were 
low birth weights. The average duration of hospitalisation post-delivery for neonates 
was 9.2 days (min – 0; max – 70 days). Neonates born to black African mothers 
significantly had lower survival rates than those born to mothers of mixed ancestry 
(5.6% vs 94.4%; p=0.001) (Figure 3) 
3. Differences in features and outcomes in pregnancies of patients with lupus 
nephritis and those without kidney involvement 
Table 4 shows the differences in pregnancy features and outcomes between patients 
with LN and those without LN. Importantly, pregnant women with LN had a higher 
frequency of flares (58.6% vs 31.3%; P=0.032), higher rate of pre-eclampsia (34.5% 
vs 12.5%, P=0.041), longer duration of hospitalisation (12.0 ± 9.1 vs 6.1 ± 5.1 days; 
P=0.004) and lower mean birth weight of the neonate (1.94 ± 1.02 vs 2.55 ± 0.95 kg; 
P=0.046) than those without kidney involvement. Patients with LN had a lower 
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neonatal survival (51.7%) at discharge compared to those without LN (65.6%), 
however, this was not significantly different (p=0.270) (Table 3).  
 
 
 
Discussion: 
Systemic lupus erythematosus is predominantly a disease of women of child-bearing 
age; it is therefore not uncommon or unexpected that these patients may present 
with pregnancy and this can be associated with hormonal changes likely to increase 
activity of lupus and affect the outcome of pregnancy. The key findings in the current 
study relates to our observation of overall increased neonatal morbidity and mortality 
especially if born to patients known with LN or patients of black African ancestry. We 
also noted a relatively high neonatal mortality in comparison with the results of 
studies published elsewhere (Table 5).7,10-15 We consider the high neonatal mortality 
in our study as a reflection of the severity of lupus activity and not of the state of 
healthcare in South Africa as all our patients were treated in a large tertiary health 
care facility. Increased lupus activity,13 previous obstetric history (i.e. previous 
pregnancy loss)16, renal involvement in lupus17 and secondary anti-phospholipid 
syndrome18 have been identified as predictors of pregnancy loss in patients with 
lupus and some of these factors might explain the poor outcome in our study.  
 
In one study, Yang et al assessing lupus activity with the SLEDAI score reported the 
incidence of preeclampsia/eclampsia, foetal loss, and preterm birth to be significantly 
higher in patients with active pregnancy related lupus compared to those with stable 
pregnancy related lupus (p<0.05).19 They also reported that despite receiving a more 
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vigorous glucocorticoid treatment, mothers with active pregnancy related lupus had a 
poorer prognosis compared to those with stable lupus in pregnancy (p<0.001).19 
Although lupus activity scores were not directly assessed in our study, activity was 
indirectly measured through the occurrence of lupus flares which we found to be 
more common in those with LN (Table 4). Also, we observed that in 36.1% of 
mothers, there was a history of pregnancy loss in previous pregnancies and mothers 
with such history had a higher chance or recurrent loss of current pregnancy (results 
not shown). Ramsey-Goldman et al have shown in their study of SLE patients with 
either positive or negative anticardiolipin antibodies that in both groups, if there was 
an adverse outcome in their first pregnancy had at least a 50% chance of another 
adverse outcome in their second pregnancy.16 Hence, SLE patients with previous 
pregnancy loss may be at greater risk of loss of conception in subsequent 
pregnancies. Although we did not find any significant correlation between previous 
pregnancy loss and outcome in current pregnancy, this may be an important factor to 
consider in patients with SLE who become pregnant. 
We also found that LN was associated with increased flare in pregnancy (p=0.032), 
increased frequency of pre-eclampsia (p=0.041), low neonatal birth weight (p=0.046) 
and increased maternal duration of hospitalization all of which are surrogates of poor 
maternal and foetal outcomes (Table 4). One meta-analysis of pregnancy outcomes 
in patients with SLE and LN comprising of 1842 patients with 2751 pregnancies 
reported the rates of lupus flare, pre-eclampsia, spontaneous abortion, stillbirth, and 
neonatal deaths to be 25.6%, 7.6%, 16%, 3.6%, and 2.5% respectively.11 However, 
in a multicentre study of 81 women (113 pregnancies) with pre-existing biopsy-
proven LN that assessed the risk factors for complicated pregnancy (foetal loss and 
renal flares), Imbasciati et al reported nine spontaneous abortions, one stillbirth and 
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five neonatal deaths.20 They also reported that renal flares during and after 
pregnancy are not uncommon and can be predicted by renal status assessed before 
pregnancy. Taken together, these findings show that in patients with SLE and LN 
there is an increased risk of maternal and foetal complications and further supports 
the need for timing of pregnancy relative to SLE activity and multispecialty care of 
these patients. 
Finally, we report from our study lower neonatal survival for those of black African 
ancestry compared to those of mixed ancestry (p=0.001) (Figure 3). As all the 
mothers and newly born would have received the same level of care from our 
hospital, this outcome is thought to be related to an increased severity of lupus in 
those of African ethnicity or may be due to differences in other socio-demographic 
factors such as level of education, nutritional status and attitude relating to the use of 
medical facilities (the later factors were not assessed in this study). In this study, 
among patients of African ancestry, 58.3% had a flare during pregnancy compared 
to 40.8% in those of mixed ancestry. SLE has been reported to be more severe in 
those of African descent often with less favourable outcomes than in Caucasians 
and in those of poor socio-economic status.21-24 In the LUMINA study, 34 of 288 SLE 
patients had died within 5 years of study onset; most were African Americans and 
some factors that were associated with mortality included poverty, less than full-time 
employment, difficulty in accessing health care and cardiovascular and renal 
involvement.23 Ward et al also reports on univariate analyses of their study that 
mortality rates increased with age and were higher among males, blacks, those 
without private medical insurance, and those living in census tracts with lower 
household incomes in the US.24 Other factors relevant to the ethnic varience in the 
outcome may be genes related to pregression of renal disease, such as ACE 
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polymorphisms. These findings support the role of race and socio-demographic 
factors in the outcome of patients with SLE and this can be extended to the 
outcomes observed in pregnancy as in our study. The higher severity of lupus with 
increased activity during pregnancy in black African patients may suggest that such 
patients will require closer monitoring of lupus flares and perhaps a more intensive 
follow-up at the ante-natal clinics in order to improve outcome of pregnancy.  
 
Our results are limited in some ways including the retrospective design of this study 
which meant that not all patients’ records could have been obtained. For example 
the results of serological assays for SLE (anti-double stranded DNA antibodies, anti-
SSA/Ro and anti-SSB/La antibodies, antiphospholipid antibodies, C3 and C4 
compliment level) were not always available and hence not presented in our data. 
Also, the retrospective design means that the interpretation of flares (disease 
activity) was sometimes done retrospectively as the attending physicians made the 
diagnosis of flares differently and the small sample size of this study may be a 
limitation of how the results are interpreted; although other published studies have 
reported on similar sample sizes.  
Conclusion: 
Our results suggest that pregnancy in patients with SLE is associated with a 
relatively poor maternal and foetal outcome, particularly in those with LN and those 
of African descent. There is need for intensive monitoring of these patients during 
pregnancy and perhaps a multi-disciplinary approach to the management of SLE 
patients, including an obstetrician (optimally a maternal foetal medicine specialist), a 
rheumatologist, and a nephrologist. Preconception counselling in non-pregnant SLE 
patients to increase awareness of the disease should be routinely carried where the 
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goal is to optimise her health before becoming pregnant. Such an approach could 
help in reducing the relatively high maternal and foetal morbidity and mortality often 
reported in developing countries like South Africa. 
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Graphs and Tables 
 
Table 1: Baseline demographics features of SLE pregnancies 
 
 
Variable 
 
Frequency (n=61)* 
 
Age at SLE diagnosis (Years) 23.3 ± 6.3 
Age at presentation – current pregnancy (years) 27.2 ± 5.0 
Race:   
• Blacks 12 (19.7%) 
• Mixed ancestry 49 (80.3%) 
GA at presentation (weeks) 13.0 ± 6.0 
Trimester at presentation   
• First 41 (67.2%) 
• Second 17 (27.9%) 
• Third 3 (4.9%) 
Kidney involvement in SLE :  
• Lupus nephritis 29 (47.5%) 
o Proliferative LN 25 (86.2%) 
o Others 4 (13.8%) 
• No-lupus nephritis 32 (52.5%) 
History previous pregnancies (%):  
Primigravida 20 (32.8%) 
Others 41 (67.2%) 
 
* This number represents the total number of pregnancies assessed in this study. 
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Table 2: Maternal features and outcomes (n=61)* 
 
	  
 
Variable 
 
Value 
 
  
Mean gestational age at delivery (weeks) 28.9 ± 9.8 
Trimester at time of delivery (%)  
• First Trimester 11.5 
• Second Trimester 24.6 
• Third Trimester 63.9 
Method of delivery (%)  
• Normal vaginal delivery 47.5 
• Evacuation** 24.6 
• Caesarean section 27.9 
Pre-eclampsia (%)  23.0 
Previous pregnancy loss # 36.1 
  
  
	  
*	  -­‐This	  number	  represents	  the	  total	  number	  of	  pregnancies	  assessed	  in	  this	  study	  
**	  -­‐	  This	  refers	  to	  evacuation	  of	  the	  retained	  products	  of	  conception	  
#	  -­‐	  Represents	  all	  previous	  termination	  of	  pregnancy,	  stillbirths	  and	  miscarriages	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Table 3: Foetal features and outcomes  (n=61)* 
 
Variable 
 
Value 
 
Average birth weight (kg)               
 
2.24 ± 1.2 
Birth weight (%)  
• Low birth weight 54.5% 
• Normal birth weight 45.5% 
Mean duration of Hospitatlization (days) 9.2 (0-70) [ min –max] 
Status at birth (%)  
• Alive 64.0 
• Medical termination 3.3 
• Miscarriage 23.0 
• Stillbirth 9.8 
Outcome at discharge (%)  
• Alive 59.0 
• Died 41.0 
 
*	  The	  number	  represents	  the	  total	  number	  of	  deliveries	  assessed	  in	  this	  study	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Table 4: Differences in pregnancy outcomes between patients with lupus 
nephritis and patients with SLE without nephritis 
	  
	  
Variable	  
	  
Lupus	  Nephritis	  
(n=29)	  
	  
SLE	  without	  
nephritis	  
(n=32)	  
	  
	  
P-­‐value	  
	  
	  
Mean	  gestational	  age	  at	  delivery	  (weeks)	  
	  
28.0	  ±	  9.0	  
	  
29.6	  ±	  10.6	  
	  
0.532	  
	  
Flare	  (%)	  
	  
58.6	  
	  
31.3	  
	  
0.032	  
	  
Pre-­‐eclampsia	  (%)	  
	  
34.5	  
	  
12.5	  
	  
0.041	  
	  
Mean	  Maternal	  Hospital	  stay	  (days)	  
	  
12.0	  ±	  9.1	  
	  
6.1	  ±	  5.1	  
	  
0.004	  
	  
Pregnancy	  outcomes	  (%)	  
	   	   	  
0.218	  
• Miscarriage	   20.7	   25.0	   	  
• Medical	  termination	   6.9	   0	   	  
• Still	  birth	   10.3	   9.4	   	  
• Preterm	  live	  birth	   44.8	   28.1	   	  
• Term	  live	  birth	   17.2	   37.5	   	  
	  
Mode	  of	  delivery	  (%)	  
	   	   	  
0.427	  
• Evacuation**	   24.1	   25.0	   	  
• Normal	  vaginal	  delivery	   55.2	   40.6	   	  
• Caesarean	  section	  	   20.7	   34.4	   	  
	  
Neonatal	  outcomes	  
	   	   	  
• Alive	  on	  discharge	  (%)	   51.7	   65.6	   0.270	  
• Mean	  birth	  weight	  (kg)	   1.94	  ±	  1.02	   2.55	  ±	  0.95	   0.046	  
• Mean	  neonatal	  hospitalisation	  (days)	  [Min-­‐Max]	   9.13	  [1	  –	  70]	   9.24	  [0	  –	  52]	   0.984	  
	  
	  
**	  -­‐	  This	  refers	  to	  evacuation	  of	  retained	  products	  of	  conception	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Table 5:  Pregnancy outcomes reported from various studies worldwide 
	  
 
Country 
 
Author (Year) [Ref] 
 
Number of 
pregnancies 
 
Pregnancy outcomes 
 
    
Miscarriage (%) 
 
Premature 
deliveries (%) 
 
 
Live Birth (%) 
 
China 
 
Liu et al. (2012) 10 
 
111 
 
22.5 
 
25.2 
 
74.8 
 
Systemic review 
& meta-analysis 
 
Smyth et al. (2010) 11 
 
2751 
 
16 * 
 
39.4 
 
74.5 
 
Portugal 
 
Carvalheiras et al. 
(2010)12 
 
51 
 
6 
 
16 
 
74 
 
USA 
 
Clowse et al.(2005)13 
 
267 
 
7 
 
40 
 
85.8 
 
South Africa 
 
Whitelaw et al.  (2008) 7 
 
47 
 
21 
 
39 
 
77 
 
India 
 
Chandran et al. (2004)14 
 
52 
 
28.6 
 
1.9 
 
46.1 
 
Taiwan 
 
Wong et al (2006) 15 
 
24 
 
8.3 
 
33.3 
 
91.6 
 
This study 
 
Mbuli et al (2015) 
 
61 
 
23 
 
36.1 
 
64.0 
	  
*	  Excluded	  5.9%	  induced	  abortions	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Graph 1: Main clinical manifestation of SLE in all the pregnancies assessed 
 
 
 
	  
*	  Others	  features	  of	  SLE	  and	  immune	  thrombocytopenic	  purpura	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Graph 2: Organ involvement during flares in SLE pregnant patients	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
No	   Skin	   Kidney	   Joint	  -­‐	  skin	   Joint	  -­‐kidney	   Joint	  
55.7%	  
9.8%	  
23.0%	  
8.2%	  
1.6%	   1.6%	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Graph 3: Neonatal discharge outcomes by maternal race	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Appendices 
	  
Appendix 1: 2012 SLICC criteria:  
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Appendix 2: Faculty of Health Sciences (UCT) ethics approval 
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